Sign Up
OverviewAPI
Predicine, Inc. has unveiled the PredicineCARE™ NGS Kit for comprehensive genomic profiling in cancer, leveraging NGS technology on liquid biopsy samples. The FDA-designated breakthrough device detects genetic alterations in cancer-related genes, emphasizing decentralized lab testing benefits. Predicine's focus on precision oncology includes global operations and liquid biopsy solutions for treatment selection and early detection.

Ask a question